• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Sanofi touts patient-driven dose titration of Toujeo insulin glargine injection

September 14, 2017 By Sarah Faulkner

SanofiSanofi (NYSE:SNY) today touted data from the Take Control trial of its Toujeo insulin glargine product in patients with Type II diabetes.

The study compared patients using Toujeo with a titration algorithm managed by the patient, compared to patients whose dose adjustment was decided by their physicians.

The 631-patient trial revealed that after six months, patients with Type II diabetes who used patient-driven titration experienced improvement in HbA1c levels compared with patients who followed physician-driven titration.

The proportion of patients who reached the pre-determined blood glucose target without experiencing hypoglycemia was 67.5% in the patient-driven titration group, while 58.4% in the group using physician-driven titration met the target without hypoglycemia.

Similar proportions of patients in both groups had at least one severe or confirmed hypoglycemic event, the company reported. Full results from the trial are slated to be announced next year.

“The results of the Take Control study demonstrate that patients can make a critical contribution to work toward their own effective blood sugar target when they are well trained and using a basal insulin such as Toujeo,” Riccardo Perfetti, Sanofi’s VP of DCV medical affairs, said in prepared remarks.

See the best minds in medtech live at DeviceTalks Boston on Oct. 2. 

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Pharmaceuticals, Wall Street Beat Tagged With: Sanofi-Aventis

IN CASE YOU MISSED IT

  • Abbott could pave new roads in diabetes management with dual sensor on the horizon
  • Tandem Diabetes Care pairs t:slim X2 pump with Abbott FreeStyle Libre 3 Plus in U.S.
  • Ypsomed, CamDiab to integrate Abbott dual glucose-ketone sensor into automated insulin delivery system
  • PharmaSens, SiBionics collab on all-in-one insulin patch pump
  • Beta Bionics to pair iLet automated insulin delivery system with Abbott’s dual glucose-ketone sensor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS